Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…
biospace · 1mo ago

Data sources

ClinicalTrials.gov

last refreshed 35m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

AG-181

updated 3mo ago

by $AGIO AGIOS PHARMACEUTICALS, INC.

community read0 votes

🐶 often sniffed alongside

top 2

all catalysts(1)

phase 1 initiation · 1

Agios Pharmaceuticals Inc — AG-181 (Phase I Trial Initiation)

AG-181

→

Trials studying AG-181

phase1A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuriarecruitingn=20
phase1Single and Multiple Ascending Dose Study and Food Effect Study for AG181completedn=88

News(1)

Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…
biospace · 1mo ago

Data sources

ClinicalTrials.gov

last refreshed 35m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

AG-181

🐶 often sniffed alongside

all catalysts(1)

Trials studying AG-181

News(1)

Report a data issue

comments(0)

AG-181

🐶 often sniffed alongside

all catalysts(1)

Trials studying AG-181

News(1)

Report a data issue

comments(0)